Hims & Hers Drives the Consumer-Centric Transformation in Digital Care

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, operates at the intersection of digital health and consumer wellness, leveraging a vertically integrated telehealth platform to provide personalized, subscription-based care. Its service model blends a direct-to-consumer approach with a broad spectrum of health offerings — ranging from sexual health and dermatology to weight loss and, soon, hormonal health — supported by a network of nearly 1,500 licensed providers. HIMS’ infrastructure integrates provider consultations, pharmacy services and app-based tools, allowing patients to receive tailored treatment plans, ongoing monitoring and proactive support without the constraints of traditional in-person care.

Central to its industry positioning is the emphasis on accessibility, personalization and scalability. Hims & Hers uses data from millions of clinical interactions to refine its offerings, empowering providers with flexible treatment options and enabling rapid adjustments based on patient feedback. Subscription revenue dominates its model, ensuring predictable income streams, while fostering deeper patient engagement and retention. By integrating lab testing capabilities, HIMS aims to expand into preventive and longevity-focused care, further aligning with industry trends toward proactive health management.

This strategy places Hims & Hers alongside other telehealth leaders, but with a more consumer-centric brand identity and marketing reach. Its blend of digital-first delivery, vertically integrated operations and specialization in underserved or stigmatized health categories mirrors broader sector trends toward hybrid, tech-enabled healthcare ecosystems. With planned international expansion into markets like the U.K., Germany and Canada, and a focus on scaling AI-driven personalization, Hims & Hers’ model is both adaptive to evolving patient expectations and positioned to capture growth in the rapidly expanding global telehealth industry.

TDOC & DOCS’ Industry & Service Model Overlap

Teladoc Health, Inc. TDOC operates as a global leader in virtual healthcare, offering integrated services across general medical, mental health, chronic condition management and specialty care. Teladoc Health combines a subscription-based enterprise model with per-visit fees, serving employers, health plans, hospitals and consumers directly. By uniting telehealth delivery with AI-driven data analytics, Teladoc Health addresses preventive, acute and ongoing care needs — mirroring industry trends toward scalable, tech-enabled, whole-person healthcare solutions.

Doximity, Inc. DOCS functions as a physician-first digital platform, connecting more than 80% of U.S. doctors and providing workflow tools, secure communications, telehealth and AI-assisted documentation. Doximity blends a free professional network for medical practitioners with subscription-based Marketing, Hiring and Workflow Solutions for health systems and pharmaceutical companies. This dual-sided platform approach positions Doximity squarely within the telehealth and healthcare SaaS landscape, aligning with industry models that leverage network effects, engagement-driven monetization and integrated digital care tools.

HIMS’ Price Performance, Valuation and Estimates

Shares of Hims & Hers have gained 106.7% year to date, outperforming the industry’s growth of 17.8%.

HIMS’ forward 12-month P/S of 4.2X is lower than the industry’s average of 5.6X, but is higher than its three-year median of 2.3X. It carries a Value Score of D.

The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 137% improvement from 2024.

Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research